55 results
Keyword Docetaxel Remove keyword
Medicine type
Additional monitoring Remove Additional monitoring filter
Generic Remove Generic filter
Biosimilar Remove Biosimilar filter
Orphan medicine Remove Orphan medicine filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Mylan
docetaxel, anhydrous, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 31/01/2012,
, Revision: 6, Withdrawn, Last updated: 12/03/2015
Rev. 1 Public statement Docetaxel Mylan Cessation of validity … marketing authorisation of Docetaxel Mylan docetaxel) ceased to be valid in the … S.A.S., had not marketed Docetaxel Mylan in the EU since its … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Teva
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/01/2010,, Revision: 17, Authorised, Last updated: 05/08/2019
summary for the public Docetaxel Teva docetaxel This is a summary of the … assessment report (EPAR) for Docetaxel Teva. It explains how the … the conditions of use for Docetaxel Teva. What is … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Accord
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 22/05/2012,, Revision: 12, Authorised, Last updated: 21/06/2019
summary for the public Docetaxel Accord docetaxel This is a summary of the … assessment report (EPAR) for Docetaxel Accord. It explains how … the conditions of use for Docetaxel Accord. What is … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Kabi
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 22/05/2012,, Revision: 12, Authorised, Last updated: 14/06/2019
summary for the public Docetaxel Kabi docetaxel This is a summary of the … assessment report (EPAR) for Docetaxel Kabi. It explains how the … the conditions of use for Docetaxel Kabi. What is … -
List item
Withdrawn application: Docetaxel SUN
docetaxel, date of withdrawal: 06/06/2016, Initial authorisation, Last updated: 29/09/2016authorisation application for Docetaxel Sun docetaxel) On 6 June 2016, Sun … marketing authorisation for Docetaxel Sun, for the treatment of … types of cancer. What is Docetaxel Sun … -
List item
Withdrawn application: Docetaxel Mylan
docetaxel, date of withdrawal: 08/03/2010, Initial authorisation, Last updated: 26/03/2010authorisation application for Docetaxel Mylan docetaxel) On 8 March 2010, Mylan … marketing authorisation for Docetaxel Mylan intended to be used … neck cancer. What is Docetaxel Mylan … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Teva Pharma
docetaxel, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Prostatic Neoplasms
Date of authorisation: 21/01/2011,, Revision: 6, Withdrawn, Last updated: 21/01/2014
Public statement on Docetaxel Teva Pharma 7 Westferry … Public statement on Docetaxel Teva Pharma Cessation of … marketing authorisation for Docetaxel Teva Pharma … -
List item
Human medicine European public assessment report (EPAR): Taxespira (previously Docetaxel Hospira UK Limited )
docetaxel trihydrate, Stomach Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 28/08/2015,, Revision: 8, Withdrawn, Last updated: 15/10/2019
Taxespira (previously Docetaxel Hospira UK Limited … Taxespira (previously Docetaxel Hospira UK Limited ) Stomach … Taxespira (previously Docetaxel Hospira UK Limited docetaxel docetaxel trihydrate … -
List item
Human medicine European public assessment report (EPAR): Docefrez
docetaxel, Stomach Neoplasms, Adenoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms
Date of authorisation: 10/05/2010,, Revision: 1, Withdrawn, Last updated: 14/06/2012
Docefrez, INN-docetaxel 7 Westferry Circus … statement on Docefrez (Docetaxel) Withdrawal of the marketing … medicinal product Docefrez (docetaxel), which had been approved … -
List item
Human medicine European public assessment report (EPAR): Kanjinti
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 16/05/2018,
, 
, Revision: 6, Authorised, Last updated: 29/11/2019
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Ogivri
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 12/12/2018,, , Revision: 2, Authorised, Last updated: 05/08/2019
medicines: with paclitaxel or docetaxel, or with another type of medicine … -
List item
Human medicine European public assessment report (EPAR): Ontruzant
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017,, , Revision: 4, Authorised, Last updated: 07/10/2019
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Herzuma (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 08/02/2018,, , Revision: 7, Authorised, Last updated: 14/02/2020
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Trazimera
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/07/2018,, , Revision: 4, Authorised, Last updated: 14/01/2020
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015,, Revision: 30, Authorised, Last updated: 30/01/2020
compared with 9.4 months with docetaxel. For squamous NSCLC, a study … months in patients given docetaxel. Supportive information was … -
List item
Human medicine European public assessment report (EPAR): Capecitabine Medac
capecitabine, Colorectal Neoplasms
Date of authorisation: 19/11/2012,, Revision: 9, Authorised, Last updated: 26/11/2019
Capecitabine Medac is used with docetaxel (another anticancer medicine … -
List item
Human medicine European public assessment report (EPAR): Capecitabine Accord
capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012,, Revision: 11, Authorised, Last updated: 13/11/2019
Capecitabine Accord is used with docetaxel (another anticancer medicine … Capecitabine Accord is used with docetaxel (another anticancer medicine … -
List item
Human medicine European public assessment report (EPAR): Ecansya (previously Capecitabine Krka)
capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012,, Revision: 11, Authorised, Last updated: 28/10/2019
body). Ecansya is used with docetaxel (another anticancer medicine … body). Ecansya is used with docetaxel (another anticancer medicine … -
List item
Human medicine European public assessment report (EPAR): Capecitabine Teva
capecitabine, Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms
Date of authorisation: 20/04/2012,, Revision: 11, Authorised, Last updated: 14/10/2019
Capecitabine Teva is used with docetaxel (another anticancer medicine … Capecitabine Teva is used with docetaxel (another anticancer medicine … -
List item
Human medicine European public assessment report (EPAR): Tecentriq
atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/09/2017,, Revision: 6, Authorised, Last updated: 23/10/2019
Tecentriq is more effective than docetaxel (another cancer medicine … average while those given docetaxel lived for 10 months. In a … 10 months for patients on docetaxel. In another main study of … -
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015,, Revision: 24, Authorised, Last updated: 11/12/2019
another cancer medicine called docetaxel (around 8 months) and the … -
List item
Human medicine European public assessment report (EPAR): Capecitabine SUN
capecitabine, Stomach Neoplasms, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms
Date of authorisation: 21/06/2013,, Revision: 3, Withdrawn, Last updated: 22/12/2016
regimen. - in combination with docetaxel for the treatment of patients … Capecitabine in combination with docetaxel is indicated for the treatment … -
List item
Human medicine European public assessment report (EPAR): Zykadia (updated)
ceritinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/05/2015,, Revision: 13, Authorised, Last updated: 12/02/2020
-
List item
Human medicine European public assessment report (EPAR): Xofigo
radium Ra223 dichloride, Prostatic Neoplasms
Date of authorisation: 13/11/2013,
, , Revision: 10, Authorised, Last updated: 10/01/2020
-
List item
Human medicine European public assessment report (EPAR): Tevagrastim (updated)
filgrastim, Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer
Date of authorisation: 15/09/2008,, Revision: 12, Authorised, Last updated: 05/02/2020